Management of chronic hepatitis C in HIV-infected patients

AIDS

Volumn 13, Issue 5, 1999, Pages 539-546

  Soriano, Vincent ^a,c   Rodríguez Rosado, Rafael ^a   García Samaniego, Javier ^b  

^a Infectious Diseases Service   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c NONE   (Spain)

Author keywords

Hepatitis C; Interferon; Liver disease; Ribavirin

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT;

CHRONIC HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HUMANS; INTERFERON TYPE I, RECOMBINANT;

EID: 0032992454     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199904010-00002     Document Type: Review

References (74)

1. 1. Alter MJ: The epidemiology of hepatitis C in the West. Semin Liver Dis 1995, 15:5-14.
2. 2. Di Bisceglie A: Hepatitis C. Lancet 1998, 351:351-353.
3. 3. Thomas D, Vlahov D, Solomon L, et al.: Correlates of hepatitis C virus infections among drug users. Medicine (Baltimore) 1995, 74:212-220.
4. 4. Slubbe L, Soriano V, Antunes F, et al.: Hepatitis C in the EuroSIDA Cohort of European HIV-infected patients: prevalence and prognostic value. 12th World AIDS Conference. Geneva, July 1998 [abstract 22261].
5. 5. Soriano V, García-Samaniego J, Rodríguez-Rosado R, Valencia E, Muñoz F, González-Lahoz J: Impact of chronic viral liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol (in press).
6. 6. Telfer P, Sabin C, Deveraux H, et al.: The progression of HCV-associated liver disease in a cohort of haemophilia patients. Br J Haematol 1994, 87:555-561.
7. 7. Martin P, Di Bisceglie A, Kassianides C, Lisker-Melman M, Hoofnagle J: Rapidly progressive non-A, non-B hepatitis in patients with HIV infection. Gastroenterology 1989, 97:1559-1561.
8. 8. Eyster M, Diamondstone L, Lien J, et al.: Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfeclion with HIV. J AIDS Hum Retrovirol 1993, 6:602-610.
9. 9. Thomas D, Shih J, Alter H, et al.: Effect of HIV on hepatitis C virus infection among injecting drug users. J Infect Dis 1996, 174:690-695.
10. 10. Sánchez-Quijano A, Andreu J, Gavilán F, et al.: Influence of HIV-1 on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995, 14:949-953.
11. 11. Soto B, Sánchez-Quijano A, Rodrigo L, et al.: HIV infection modifies the natural history of chronic parenterally acquired hepatitis C with an unusually rapid progression to cirrhosis. A multicenter study on 547 patients. J Hepatol 1997, 26:1-5.
12. 12. Piroth L, Duong M, Quantin C, et al.: Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998, 12:381-388.
13. 13. Battegay M: Immunity to hepatitis C virus. A further piece of the puzzle. Hepatology 1996, 24:961-963.
14. 14. Palella F, Delaney K, Moorman A, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
15. 15. Hogg R, Heath K, Yip B, et al.: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279:450-454.
16. 16. Marschner I, Collier A, Coombs R. et al.: Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998, 177:40-47.
17. 17. Houghton M, Weiner A, Han J, et al.: Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 1991, 14:381-388.
18. 18. Lemin H: Retrovirus variation and reverse transcription: abnormal strand transfers result in genetic variation. Proc Natl Acad Sci USA 1993, 90:6900-6903.
19. 19. Brechot C: Hepatitis C virus genetic variability: clinical implications. Am J Gastroenterol 1994, 84:41-47.
20. 20. Simmonds P: Variability of hepatitis C virus. Hepatology 1995, 21:570-583.
21. 21. Domingo E, Holland J: RNA virus mutations and fitness for survival. Annu Rev Microbiol 1997, 51:151-178.
22. 22. Myers G, Korber B, Berzofsky J, et al.: A compilation and analysis of nucleic acid and amino acid sequences. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 1997.
23. 23. Simon E, Mauclere P, Roques P, et al.: Identification of a new HIV type 1 distinct from group M and group O. Nat Med 1998, 4:1032-1037.
24. 24. Zeuzem S, Lee J, Roth W: Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alpha. Hepatology 1997, 25:740-744.
25. 25. Nousbaum J, Pol S, Nalpas B, et al.: Hepatitis C virus type 1b (11) infection in France and Italy. Ann Intern Med 1994, 122:161-168.
26. 26. Lam N, Neumann A, Gretch D, et al.: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 1997, 26:226-231.
27. 27. Yasui K, Okanoue T, Murakami Y, et al.: Dynamics of hepatitis C viraemia following interferon administration. J Infect Dis 1998, 177:1475-1479.
28. 28. Neumann A, Lam N, Dahari H, et al.: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
29. 29. Henrard D, Phillips J, Muenz L, et al.: Natural history of HIV-1 cell-free viraemia. JAMA 1495, 274:554-558.
30. 30. Yoshimura E, Hayashi J, Ueno K: No significant changes in levels of HCV RNA by competitive polymerase chain reaction in blood samples from patients with chronic HCV infection. Dig Dis Sci 1997, 42:772-777.
31. 31. Cribier B, Rey D, Schmitt C, et al.: High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995, 9:1131-1136.
32. 32. Soriano V, Bravo R, Mas A, et al.: Impact of immunosuppression caused by HIV infection on the replication of hepatitis C virus. Vox Sang 1995, 69:259-260.
33. 33. Collier J, Heathcote J: Hepatitis C viral infection in the immunosuppressed patient. Hepatology 1998, 27:2-6.
34. 34. Eyster M, Fried M, Di Bisceglie A, Goedert J: Increasing hepatitis C virus RNA levels in hemophiliacs; relationship to HIV infection and liver disease. Blood 1994, 84:1020-1023.
35. 35. National Institutes of Health: Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997, 26 (Suppl 1):2-10.
36. 36. Lenzo NP, Garas BA, French MA: Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report [letter]. AIDS 1997, 11:1294-1296.
37. 37. Karras A, Rabian C, Zylbergerg H, et al.: Severe anoxic hepatic necrosis in an HIV-1-hepatitis C virus co-infected patient starting antiretroviral triple combination therapy [letter]. AIDS 1998, 12:827-829.
38. 38. Rodríguez-Rosado R, García-Samaniego J, Soriano V: Hepatotoxicity after introduction of highly active antiretroviral therapy [letter]. AIDS 1998, 12:1256.
39. 39. Poynard T, Leroy V, Cohard M, et al.: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996, 24:778-789.
40. 40. Soriano V, García-Samaniego J, Bravo R, et al.: Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 1996, 23:585-591.
41. 41. Soriano V, Bravo R, García-Samaniego J, et al.: Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. AIDS 1997, 11:400-401.
42. 42. Poynard T, Bedossa P, Opolon P, et al.: Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997, 349:825-832.
43. 43. García-Samaniego J, Soriano V, Castilla J, et al.: Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. Am J Gastroenterol 1997, 92:1130-1134.
44. 44. Poynard T, Bedossa P, Chevallier M, et al.: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995, 332:1457-1462.
45. 45. Zeuzem S, Schmidt J, Lee J, von Wagner M, Teuber G, Roth WK: Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998, 28:245-251.
46. 46. Nakamura H, Ito H, Kimura Y, et al.: The importance of initial daily administration of interferon alpha for the eradication of hepatitis C virus in patients with chronic hepatitis C: a multicenter randomized trial. Hepatogastroenterology 1998, 43:1045-1055.
47. 47. Carpenter C, Fischl M, Hammer S, et al.: Antiretroviral therapy for HIV infection in 1998. JAMA 1998, 280:78-86.
48. a gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996, 334:77-81.
49. 49. Rispeter K, Lu M, Zibert A, Wiese M, de Oliveira J, Roggendorf M: The "interferon sensitivity determining region" of hepatitis C virus is a stable sequence element. J Hepatol 1998, 29:352-361.
50. 50. Lai M, Kao J, Yang P, et al.: Long-term efficacy of ribavirin plus interferon alfa in the treatment of hepatitis C. Gastroenterology 1996, 111:1307-1312.
51. 51. Reichard O, Norkrans G, Frydén A, et al.: Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998, 351:83-87.
52. 52. Brown J: Efficacy of combined interferon and ribavirin for treatment of hepatitis C. Lancet 1998, 351:78-79.
53. 53. Smith JP: Treatment of chronic hepatitis C with Amantadine. Dig Dis Sci 1997, 42:1681-1687.
54. 54. Bonkovsky H: Therapy of hepatitis C: other options. Hepatology 1997, 26 (suppl 1) :143-151.
55. 55. Bodenheimer H, Lindsay K, Davis G, et al.: Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997, 26:473-477.
56. 56. Kim J, Morgenstern K, Lin C, et al.: Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996, 87:343-355.
57. 57. Yao N, Hesson T, Cable M, et al.: Structure of hepatitis C virus RNA helycase domain. Nat Struct Biol 1997, 4:463-467.
58. 58. Von Weizsäcker F, Wieland S, Köck J, et al.: Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides and dominant negative mutants. Hepatology 1997, 26:251-255.
59. 59. Martinot-Peignoux M, Marcellin P, Pouteau M, et al.: Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995, 22:1050-1056.
60. 60. Wong L, Fall M, Livingston M, et al.: The cost of dying of end-stage liver disease. Arch Intern Med 1997, 157:1429-1432.
61. 61. Ho D: Time to hit HIV, early and hard. N Engl J Med 1995, 333: 450-451.
62. 62. Soriano V, Bravo R, García-Samaniego J, et al.: CD4+ lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C [letter]. AIDS 1994, 8:1621-1622.
63. 63. Vento S, Di Perri G, Cruciani M, Garofano L, Concia E, Bassetti D: Rapid decline of CD4+ cells after IFNc: treatment in HIV-1 infection. Lancet 1993, 341:958-959.
64. 64. Zagury D, Lachgar A, Chams V, et al.: Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA 1998, 95:3851-3856.
65. 65. García-Samaniego J, Bravo R, Castilla J, et al.: Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients. J Hepatol 1998, 28:526-527.
66. 66. Rockstroh JK, Theisen A, Kaiser R, Sauerbruch T, Spengler U: Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV coinfected haemophiliacs. AIDS 1998, 12:829-830.
67. 67. Zhang Z, Milich D: Interferon alpha treatment induces delayed CD4+ proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy. J Infect Dis 1997, 175:1294-1301.
68. 68. Bravo R, Soriano V, García-Samaniego J, et al.: Impact of antiretroviral therapy on hepatitis C viraemia in HIV-infected patients. Antiviral Therapy 1996, 1:194.
69. 69. Rutschmann O, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin L: Impact of treatment with HIV protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998, 177:783-785.
70. 70. The Ribavirin ARC Study Group: Multicenter clinical trial of oral ribavirin in symptomatic HIV-infected patients. J AIDS Hum Retrovirol 1993, 6:32-41.
71. 71. Gilson R, Semple M, Gill S, Loveday C, Tedder R, Weller I: Lack of suppression by ribavirin of HIV viraemia. Lancet 1992, 339:1605-1606.
72. 72. Hoggard P, Kewn S, Barry M, Khoo S, Back D: Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997, 41:1231-1236.
73. 73. Japour A, Lertora J, Meehan P, et al.: A phase 1 study of the safety, pharmacokinetics, and antiviral activity of a combination of didanosine and ribavirin in patients with HIV-1 disease. ACTG 231 Protocol Team. J AIDS Hum Retrovirol 1996, 13:235-246.
74. 74. Soriano V, García-Samaniego J, Pérez-Olmeda M, González J: Efficacy and safety of interferon plus ribavirin for chronic hepatitis C in HIV-infected patients. 4th International Congress on Drug therapy in HIV infection. Glasgow, November 1998 [abstract 199A].